Why is Liquidia stock plunging? Yutrepia patent case explained

Liquidia shares plunged nearly 50% after a US court ruled against the company in a patent dispute with United Therapeutics, raising concerns over Yutrepia’s commercial prospects.

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.